Therapeutic outcomes in patients undergoing surgery after diagnosis of Cushing's disease: A single-center study
- PMID: 26477323
- DOI: 10.1507/endocrj.15-0463
Therapeutic outcomes in patients undergoing surgery after diagnosis of Cushing's disease: A single-center study
Abstract
This study aimed to investigate early and late outcomes of patients who underwent neurosurgical procedures for the preoperative diagnosis of Cushing's disease (CD). Clinical, endocrine, imaging, and histologic data from 252 patients undergoing pituitary surgery at Toranomon Hospital through the end of 2012 were entered into a database and statistically analyzed. In 22 of these patients (8.7%; positive venous sampling in 15 and negative venous sampling in 7 patients), tumors were invisible on magnetic resonance imaging (MRI) and 42.9% of them achieved remission. In the remaining 230 patients, 93.5% of those with microadenomas (n=154) and 71.1% of those with macroadenomas (n=76) achieved early postoperative remission, with recurrence rates of 2.7% and 14.8%, respectively, during a 72.5-month median follow-up. In multivariate analyses, cavernous sinus invasion (CSI; odds ratio [OR], 13.0), type of surgery (OR, 4.0), and tumor size (OR, 2.7) were significant preoperative factors affecting early postoperative results, whereas peak cortisol levels ≥9.4 μg/dL in response to corticotropin-releasing hormone (CRH) and CSI were significant factors predicting recurrence. Tumor recurrence was more common in patients with non-densely granulated adenomas than in patients with densely granulated adenomas. We propose that the higher remission and lower recurrence rates in this series are due to our surgical strategies, including extracapsular tumor removal, aggressive resection of tumors with CSI, extended transsphenoidal surgery (TSS), or a combined approach for large/giant adenomas. Appropriate multimodal treatments, including radiotherapy, medication, and repeated surgery in patients with persistent or recurrent CD, could result in better overall outcomes than previously achieved.
Similar articles
-
Endoscopic transsphenoidal pituitary surgery: a good and safe primary treatment option for Cushing's disease, even in case of macroadenomas or invasive adenomas.Eur J Endocrinol. 2013 Aug 28;169(3):329-37. doi: 10.1530/EJE-13-0325. Print 2013 Sep. Eur J Endocrinol. 2013. PMID: 23786985
-
Dynamics of postoperative serum cortisol after transsphenoidal surgery for Cushing's disease: implications for immediate reoperation and remission.J Neurosurg. 2018 Nov 1;129(5):1268-1277. doi: 10.3171/2017.6.JNS17635. Epub 2017 Dec 22. J Neurosurg. 2018. PMID: 29271716
-
Outcome of transsphenoidal surgery for Cushing's disease: a high remission rate in ACTH-secreting macroadenomas.Clin Neurol Neurosurg. 2009 Jun;111(5):442-9. doi: 10.1016/j.clineuro.2008.12.011. Epub 2009 Feb 5. Clin Neurol Neurosurg. 2009. PMID: 19200645
-
Outcomes of pituitary surgery for Cushing's disease: a systematic review and meta-analysis.Pituitary. 2020 Oct;23(5):595-609. doi: 10.1007/s11102-020-01066-8. Pituitary. 2020. PMID: 32691356
-
Prognostic Factors of Long-Term Remission After Surgical Treatment of Cushing's Disease.Endocrinol Metab Clin North Am. 2018 Jun;47(2):335-347. doi: 10.1016/j.ecl.2018.02.002. Epub 2018 Apr 9. Endocrinol Metab Clin North Am. 2018. PMID: 29754635 Review.
Cited by
-
The experience with transsphenoidal surgery and its importance to outcomes.Pituitary. 2018 Oct;21(5):545-555. doi: 10.1007/s11102-018-0904-4. Pituitary. 2018. PMID: 30062664 Review.
-
Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series.J Endocrinol Invest. 2020 May;43(5):631-639. doi: 10.1007/s40618-019-01151-1. Epub 2019 Nov 26. J Endocrinol Invest. 2020. PMID: 31773581
-
Cushing's Disease.J Clin Med. 2019 Nov 12;8(11):1951. doi: 10.3390/jcm8111951. J Clin Med. 2019. PMID: 31726770 Free PMC article. Review.
-
Usefulness of desmopressin testing to predict relapse during long-term follow-up in patients in remission from Cushing's disease.Endocr Connect. 2017 Nov;6(8):791-799. doi: 10.1530/EC-17-0292. Epub 2017 Oct 10. Endocr Connect. 2017. PMID: 29018154 Free PMC article.
-
Optimizing MR imaging for intraoperative image guidance in sellar pathologies.Pituitary. 2020 Jun;23(3):266-272. doi: 10.1007/s11102-020-01035-1. Pituitary. 2020. PMID: 32170516 Free PMC article.